The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study. Using anti-acetylcholine receptor ...

On World Rare Diseases Day, read on to learn more about Myasthenia Gravis, a complex autoimmune disorder that requires careful management. Early diagnosis and appropriate treatment can help ...

antibodies. Higher Quantitative Myasthenia Gravis-Revised (QMG) scores, indicating more severe disease based on clinician ratings, have been associated with frequent exacerbations. New data from ...

Guggenheim reiterated their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a report issued on Monday ...

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

Unlike the monoclonal antibodies eculizumab and ravulizumab ... that are integral to the pathogenesis of generalized myasthenia gravis," noted Richard Nowak, MD, MS, of Yale University in New ...

(NASDAQ:ARGX – Free Report) had its price target increased by Guggenheim from $775.00 to $1,100.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the ...

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profileof VYVGART and VYVGART HytrulogMG patients on VYVGART ...

We met the primary end point, which was to show improvement in MG-ADL score—that's myasthenia gravis activities of daily living score—at 6 months, and it was in a broad group of antibody ...